Cantor Fitzgerald Issues Positive Outlook for TVTX Earnings

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share (EPS) estimate for Travere Therapeutics to ($1.25), up from a prior estimate of ($1.32), indicating a positive outlook for the company.
• The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share, and FY2026 earnings are projected at $1.00 EPS.
• Travere Therapeutics' stock carries an average rating of "Moderate Buy" with a consensus target price of $32.21, supported by multiple buy ratings from analysts.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the company will post earnings per share of ($1.25) for the year, up from their previous estimate of ($1.32). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Cantor Fitzgerald also issued estimates for Travere Therapeutics' FY2026 earnings at $1.00 EPS.

TVTX has been the topic of several other research reports. Wedbush boosted their target price on Travere Therapeutics from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Thursday. Citigroup reissued a "buy" rating on shares of Travere Therapeutics in a research report on Sunday. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Travere Therapeutics in a research report on Tuesday, July 1st. Scotiabank reissued an "outperform" rating on shares of Travere Therapeutics in a research report on Thursday. Finally, Guggenheim reissued a "buy" rating and set a $47.00 target price on shares of Travere Therapeutics in a research report on Monday, April 14th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $32.21.

Travere Therapeutics Stock Performance

NASDAQ:TVTX opened at $16.94 on Monday. The company has a debt-to-equity ratio of 9.50, a current ratio of 2.00 and a quick ratio of 1.98. Travere Therapeutics has a 1 year low of $8.31 and a 1 year high of $25.29. The stock's 50 day simple moving average is $15.46 and its two-hundred day simple moving average is $17.76. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -8.30 and a beta of 0.74.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.14. The company had revenue of $94.84 million for the quarter, compared to the consensus estimate of $100.18 million. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%. The firm's quarterly revenue was up 111.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.65) EPS.

Institutional Trading of Travere Therapeutics

Hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC purchased a new position in Travere Therapeutics during the first quarter worth approximately $182,000. Northern Trust Corp boosted its position in Travere Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 754,395 shares of the company's stock worth $13,142,000 after purchasing an additional 76,358 shares in the last quarter. Wellington Management Group LLP purchased a new position in Travere Therapeutics during the fourth quarter worth approximately $583,000. Bank of New York Mellon Corp boosted its position in Travere Therapeutics by 7.9% during the first quarter. Bank of New York Mellon Corp now owns 233,942 shares of the company's stock worth $4,192,000 after purchasing an additional 17,079 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Travere Therapeutics by 5,072.9% during the first quarter. GAMMA Investing LLC now owns 10,501 shares of the company's stock worth $188,000 after purchasing an additional 10,298 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.